IBI363 for advanced melanoma after standard treatment
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new drug called IBI363 for people with advanced melanoma that has progressed after standard treatment. It aims to see if IBI363 can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced melanoma that has gotten worse after at least one standard treatment (like chemo, immunotherapy, or targeted therapy).
- You have at least one tumor that can be measured on a scan (like a CT or MRI).
- You are able to take care of yourself (walking, eating, bathing) or need only a little help (ECOG score 0 or 1).
- Your doctor thinks you are likely to live at least 3 more months.
- You are not pregnant or breastfeeding, and you agree to use birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called PRJ1-3024 for people with advanced melanoma that has not responded to standard treatment. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
This trial tests a new drug called IBI363 for people with advanced solid tumors. It aims to see if the drug is safe and effective. You may be able to join if you are generally well and have not had other cancer treatments recently.
This trial tests a new drug, IBI363, compared to the standard drug pembrolizumab (Keytruda) for people with advanced mucosal or acral melanoma who have not had treatment before. It aims to see if IBI363 works better or as well as the usual treatment.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This study tests an experimental drug called IBI363 given before surgery for people with stage II to III non-small cell lung cancer that can be removed. The goal is to see if it helps shrink the tumor and improve outcomes.
This study tests a new combination therapy (IBI363 with other drugs) for advanced colorectal cancer that is pMMR/MSI-L/MSS. It aims to understand how the immune system around the tumor changes during treatment.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.